Drug Profile
Research programme: cannabinoid therapeutics - Emerald/VivaCell
Alternative Names: APH-1305; Neurodegenerative disease therapeutics - Aphios Corporation/VivaCell Biotechnology Espana; VCE-003; VCE-003.1; Δ9 Tetrahydrocannabinoid; Δ9 THCALatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Aphios Corporation; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
- Developer Aphios Corporation; Emerald Health Sciences; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
- Class Cannabinoids; Quinones
- Mechanism of Action Cannabinoid receptor CB2 agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple sclerosis
Highest Development Phases
- No development reported Fibrosis; Multiple sclerosis; Scleroderma
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Fibrosis in Spain (PO)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Scleroderma in Spain (PO)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis in Spain (PO)